Literature DB >> 32982644

Endocrine-Resistant Breast Cancer: Mechanisms and Treatment.

Andreas D Hartkopf1, Eva-Maria Grischke1, Sara Y Brucker1.   

Abstract

BACKGROUND: Endocrine treatment is one of the most effective therapies for estrogen receptor-positive breast cancer. However, most tumors will develop resistance to endocrine therapy as the cancer progresses. This review focuses on the mechanisms and markers of endocrine-resistant breast cancer. In addition, current and future strategies to overcome endocrine resistance are discussed.
SUMMARY: Several molecular mechanisms of endocrine resistance have been identified, including alterations in the ESR1 gene or in the PIK3CA/mTOR pathway. Meanwhile, CDK4/6, mTOR, and PI3K inhibition have shown to improve the efficacy of endocrine treatment and new promising approaches are being developed. KEY MESSAGE: Overcoming primary or acquired resistance to endocrine treatment remains a major challenge. Since the molecular mechanisms of endocrine resistance are manifold, optimal combination and sequencing strategies will have to be developed in the future.
Copyright © 2020 by S. Karger AG, Basel.

Entities:  

Keywords:  Breast cancer; Endocrine resistance; Endocrine treatment; Metastases

Year:  2020        PMID: 32982644      PMCID: PMC7490658          DOI: 10.1159/000508675

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN: 1661-3791            Impact factor:   2.860


  80 in total

1.  Will the real Cowden syndrome please stand up: revised diagnostic criteria.

Authors:  C Eng
Journal:  J Med Genet       Date:  2000-11       Impact factor: 6.318

2.  Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.

Authors:  John F R Robertson; Igor M Bondarenko; Ekaterina Trishkina; Mikhail Dvorkin; Lawrence Panasci; Alexey Manikhas; Yaroslav Shparyk; Servando Cardona-Huerta; Kwok-Leung Cheung; Manuel Jesus Philco-Salas; Manuel Ruiz-Borrego; Zhimin Shao; Shinzaburo Noguchi; Jacqui Rowbottom; Mary Stuart; Lynda M Grinsted; Mehdi Fazal; Matthew J Ellis
Journal:  Lancet       Date:  2016-11-29       Impact factor: 79.321

3.  Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression.

Authors:  Linda Sofie Lindström; Eva Karlsson; Ulla M Wilking; Ulla Johansson; Johan Hartman; Elisabet Kerstin Lidbrink; Thomas Hatschek; Lambert Skoog; Jonas Bergh
Journal:  J Clin Oncol       Date:  2012-06-18       Impact factor: 44.544

Review 4.  Mechanisms of endocrine resistance in breast cancer.

Authors:  C Kent Osborne; Rachel Schiff
Journal:  Annu Rev Med       Date:  2011       Impact factor: 13.739

5.  A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer.

Authors:  Emily M Fox; Todd W Miller; Justin M Balko; Maria G Kuba; Violeta Sánchez; R Adam Smith; Shuying Liu; Ana María González-Angulo; Gordon B Mills; Fei Ye; Yu Shyr; H Charles Manning; Elizabeth Buck; Carlos L Arteaga
Journal:  Cancer Res       Date:  2011-09-09       Impact factor: 12.701

Review 6.  Breast cancer.

Authors:  Nadia Harbeck; Frédérique Penault-Llorca; Javier Cortes; Michael Gnant; Nehmat Houssami; Philip Poortmans; Kathryn Ruddy; Janice Tsang; Fatima Cardoso
Journal:  Nat Rev Dis Primers       Date:  2019-09-23       Impact factor: 52.329

7.  Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study.

Authors:  John F R Robertson; Justin P O Lindemann; Antonio Llombart-Cussac; Janusz Rolski; David Feltl; John Dewar; Laura Emerson; Andrew Dean; Matthew J Ellis
Journal:  Breast Cancer Res Treat       Date:  2012-10-13       Impact factor: 4.872

8.  Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2.

Authors:  Gabriel N Hortobagyi; David Chen; Martine Piccart; Hope S Rugo; Howard A Burris; Kathleen I Pritchard; Mario Campone; Shinzaburo Noguchi; Alejandra T Perez; Ines Deleu; Mikhail Shtivelband; Norikazu Masuda; Shaker Dakhil; Ian Anderson; Douglas M Robinson; Wei He; Abhishek Garg; E Robert McDonald; Hans Bitter; Alan Huang; Tetiana Taran; Thomas Bachelot; Fabienne Lebrun; David Lebwohl; José Baselga
Journal:  J Clin Oncol       Date:  2015-10-26       Impact factor: 44.544

9.  Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up.

Authors:  H S Rugo; R S Finn; V Diéras; J Ettl; O Lipatov; A A Joy; N Harbeck; A Castrellon; S Iyer; D R Lu; A Mori; E R Gauthier; C Huang Bartlett; K A Gelmon; D J Slamon
Journal:  Breast Cancer Res Treat       Date:  2019-01-10       Impact factor: 4.872

10.  Activating ESR1 mutations in hormone-resistant metastatic breast cancer.

Authors:  Dan R Robinson; Yi-Mi Wu; Pankaj Vats; Fengyun Su; Robert J Lonigro; Xuhong Cao; Shanker Kalyana-Sundaram; Rui Wang; Yu Ning; Lynda Hodges; Amy Gursky; Javed Siddiqui; Scott A Tomlins; Sameek Roychowdhury; Kenneth J Pienta; Scott Y Kim; J Scott Roberts; James M Rae; Catherine H Van Poznak; Daniel F Hayes; Rashmi Chugh; Lakshmi P Kunju; Moshe Talpaz; Anne F Schott; Arul M Chinnaiyan
Journal:  Nat Genet       Date:  2013-11-03       Impact factor: 38.330

View more
  10 in total

1.  A Phase Ib Dose Escalation Trial of RO4929097 (a γ-secretase inhibitor) in Combination with Exemestane in Patients with ER + Metastatic Breast Cancer (MBC).

Authors:  Julie A Means-Powell; Ingrid A Mayer; Roohi Ismail-Khan; Luis Del Valle; Debra Tonetti; Vandana G Abramson; Melinda S Sanders; Richard M Lush; Claudia Sorrentino; Samarpan Majumder; Lucio Miele
Journal:  Clin Breast Cancer       Date:  2021-10-28       Impact factor: 3.078

2.  Collateral-resistance to estrogen and HER-activated growth is associated with modified AKT, ERα, and cell-cycle signaling in a breast cancer model.

Authors:  Kate M Moore; Vera Cerqueira; Kenneth G MacLeod; Peter Mullen; Richard L Hayward; Simon Green; David J Harrison; David A Cameron; Simon P Langdon
Journal:  Explor Target Antitumor Ther       Date:  2022-02-28

3.  The Potential Use of Propolis as an Adjunctive Therapy in Breast Cancers.

Authors:  Dedy Hermansyah; Felix Zulhendri; Conrad O Perera; Naufal N Firsty; Kavita Chandrasekaran; Rizky Abdulah; Herry Herman; Ronny Lesmana
Journal:  Integr Cancer Ther       Date:  2022 Jan-Dec       Impact factor: 3.077

Review 4.  Management Strategies for Hyperglycemia Associated with the α-Selective PI3K Inhibitor Alpelisib for the Treatment of Breast Cancer.

Authors:  Tsvetalina Tankova; Elżbieta Senkus; Maria Beloyartseva; Simona Borštnar; Doina Catrinoiu; Mona Frolova; Alinta Hegmane; Andrej Janež; Mladen Krnić; Zoltan Lengyel; Yiola Marcou; Laura Mazilu; Bela Mrinakova; Ruth Percik; Katarina Petrakova; Gábor Rubovszky; Margarita Tokar; Eduard Vrdoljak
Journal:  Cancers (Basel)       Date:  2022-03-22       Impact factor: 6.639

5.  Endocrine resistant breast cancer: brain metastasis.

Authors:  Matthew Willman; Jonathan Willman; Brandon Lucke-Wold
Journal:  Explor Target Antitumor Ther       Date:  2022-04-26

Review 6.  Therapeutic Potential for Targeting Autophagy in ER+ Breast Cancer.

Authors:  Ryan M Finnegan; Ahmed M Elshazly; Patricia V Schoenlein; David A Gewirtz
Journal:  Cancers (Basel)       Date:  2022-09-01       Impact factor: 6.575

7.  The prognostic role of variations in tumour markers (CEA, CA15.3) in patients with metastatic breast cancer treated with CDK4/6 inhibitors.

Authors:  Federico Sottotetti; Elisa Ferraris; Barbara Tagliaferri; Raffaella Palumbo; Erica Quaquarini; Cristina Teragni; Emanuela Balletti; Claudia Leli; Andrea Premoli; Ludovica Mollica; Silvia Puglisi; Silvia Sardi; Alberto Malovini; Paolo Pedrazzoli; Antonio Bernardo
Journal:  Drugs Context       Date:  2022-09-05

Review 8.  Targeting O-GlcNAcylation to overcome resistance to anti-cancer therapies.

Authors:  Ninon Very; Ikram El Yazidi-Belkoura
Journal:  Front Oncol       Date:  2022-08-17       Impact factor: 5.738

Review 9.  Exploring new pathways in endocrine-resistant breast cancer.

Authors:  Inês Soares de Pinho; Catarina Abreu; Inês Gomes; Sandra Casimiro; Teresa Raquel Pacheco; Rita Teixeira de Sousa; Luís Costa
Journal:  Explor Target Antitumor Ther       Date:  2022-06-20

Review 10.  Targeting AKT in ER-Positive HER2-Negative Metastatic Breast Cancer: From Molecular Promises to Real Life Pitfalls?

Authors:  Benoîte Mery; Coralie Poulard; Muriel Le Romancer; Olivier Trédan
Journal:  Int J Mol Sci       Date:  2021-12-16       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.